Bayer Highlights Latest Oncology Research at ASCO 2018

Bayer announced that the latest research across its growing oncology portfolio will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place June 1-5 in Chicago.

Highlights include data on approved therapies as well as new research from Bayer’s early and late-stage pipeline compounds. In line with the theme of this year’s meeting, “Delivering Discoveries: Expanding the Reach of Precision Medicine,” the company’s research includes larotrectinib, an investigational compound jointly developed by Bayer and Loxo Oncology. The New Drug Application in the U.S. was recently submitted to the U.S. Food and Drug Administration.

Results from a randomized Phase II study investigating three dosing regimens of radium Ra 223 dichloride in bone metastatic castration-resistant prostate cancer (mCRPC) and a Phase III trial of sorafenib in desmoid tumors, sponsored by the National Cancer Institute, will be highlighted in oral presentations at the meeting. Poster presentations of note include the final analysis from the global OPTIMIS study of outcomes in patients with hepatocellular carcinoma treated with transarterial chemoembolization (TACE), safety and tolerability data of radium Ra 223 dichloride in combination with enzalutamide in patients with mCRPC and a subgroup analyses of diabetic patients from the Phase II CHRONOS-1 study of copanlisib in patients with relapsed or refractory indolent B-cell lymphoma.

About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now includes four oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

About Bayer
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.us.